Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma-A Retrospective Study.

Hadash-Bengad R, Hajaj E, Klein S, Merims S, Frank S, Eisenberg G, Yakobson A, Orevi M, Caplan N, Peretz T, Lotem M, Cohen JE.

Front Oncol. 2020 Feb 14;10:70. doi: 10.3389/fonc.2020.00070. eCollection 2020.

2.

Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.

Sartor O, Heinrich D, Mariados N, Méndez Vidal MJ, Keizman D, Thellenberg Karlsson C, Peer A, Procopio G, Frank SJ, Pulkkanen K, Rosenbaum E, Severi S, Trigo J, Trandafir L, Wagner V, Li R, Nordquist LT.

Prostate. 2019 Oct;79(14):1683-1691. doi: 10.1002/pros.23893. Epub 2019 Aug 23.

3.

Prospective analysis of in vivo landmark point-based MRI geometric distortion in head and neck cancer patients scanned in immobilized radiation treatment position: Results of a prospective quality assurance protocol.

Joint Head and Neck Radiotherapy-MRI Development Cooperative.

Clin Transl Radiat Oncol. 2017 Oct 10;7:13-19. doi: 10.1016/j.ctro.2017.09.003. eCollection 2017 Dec.

4.

Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).

Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, Piulats JM, Wolter P, Cocquyt V, Chmielowski B, Evans TRJ, Gastaud L, Linette G, Berking C, Schachter J, Rodrigues MJ, Shoushtari AN, Clemett D, Ghiorghiu D, Mariani G, Spratt S, Lovick S, Barker P, Kilgour E, Lai Z, Schwartz GK, Nathan P.

J Clin Oncol. 2018 Apr 20;36(12):1232-1239. doi: 10.1200/JCO.2017.74.1090. Epub 2018 Mar 12. Erratum in: J Clin Oncol. 2018 Dec 10;36(35):3528.

PMID:
29528792
5.

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ; SPARTAN Investigators.

N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8.

6.

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators.

N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17.

7.

Adoptive cell therapy: past, present and future.

Cohen JE, Merims S, Frank S, Engelstein R, Peretz T, Lotem M.

Immunotherapy. 2017 Jan;9(2):183-196. doi: 10.2217/imt-2016-0112. Review.

PMID:
28128715
8.

PET/CT With 68Ga-DOTA-TATE for Diagnosis of Neuroendocrine: Differentiation in Patients With Castrate-Resistant Prostate Cancer.

Gofrit ON, Frank S, Meirovitz A, Nechushtan H, Orevi M.

Clin Nucl Med. 2017 Jan;42(1):1-6.

PMID:
27775942
9.

Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL.

Engelstein R, Merims S, Eisenberg G, Cohen J, Frank S, Hamburger T, Frankenburg S, Ron I, Isacson R, Grenader T, Steinberg H, Cohen CJ, Peretz T, Lotem M.

J Immunother. 2016 Oct;39(8):321-8. doi: 10.1097/CJI.0000000000000138.

PMID:
27564312
10.

Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade.

Lotem M, Merims S, Frank S, Hamburger T, Nissan A, Kadouri L, Cohen J, Straussman R, Eisenberg G, Frankenburg S, Carmon E, Alaiyan B, Shneibaum S, Ozge Ayyildiz Z, Isbilen M, Mert Senses K, Ron I, Steinberg H, Smith Y, Shiloni E, Gure AO, Peretz T.

J Immunol Res. 2016;2016:8121985. doi: 10.1155/2016/8121985. Epub 2016 May 18.

11.

Recognizing the Magnitude of the Challenge.

Frank S.

Healthc Pap. 2016;15(4):51-3.

PMID:
27230720
12.

Radical cystectomy vs. chemoradiation in T2-4aN0M0 bladder cancer: a case-control study.

Gofrit ON, Nof R, Meirovitz A, Pode D, Frank S, Katz R, Shapiro A, Landau EH, Hidas G, Yutkin V, Duvdevani M, Wygoda M.

Urol Oncol. 2015 Jan;33(1):19.e1-19.e5. doi: 10.1016/j.urolonc.2014.09.014. Epub 2014 Nov 4.

PMID:
25445384
13.

Contemporary pharmacotherapy for the prevention of skeletal complications in patients with prostate cancer.

Sfoungaristos S, Frank SJ, Duvdevani M, Gofrit ON, Yutkin V, Katz R, Pode D, Perimenis P.

Expert Opin Pharmacother. 2014 Dec;15(17):2513-24. doi: 10.1517/14656566.2014.960390. Epub 2014 Sep 19. Review.

PMID:
25234584
14.

Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer.

Sella A, Sella T, Peer A, Berger R, Frank SJ, Gez E, Sharide D, Hayat H, Hanovich E, Kovel S, Rosenbaum E, Neiman V, Keizman D.

Clin Genitourin Cancer. 2014 Dec;12(6):428-32. doi: 10.1016/j.clgc.2014.06.007. Epub 2014 Jun 10.

PMID:
25066221
15.

Correcting the record.

Frank S.

CMAJ. 2014 Jul 8;186(10):779. doi: 10.1503/cmaj.114-0053. No abstract available.

16.

Cytologic diagnosis of chordoma in a peritoneal effusion: a case report.

Chopra S, Frank SJ, Gu M.

Acta Cytol. 2010 May-Jun;54(3):341-4.

PMID:
20518424
17.

Withdrawal of routine brucellosis testing in beef herds.

Stephen F.

Vet Rec. 2007 Apr 28;160(17):599. No abstract available.

PMID:
17468328
18.

New pyrimidine- and fluorene-containing oligo(arylene)s: synthesis, crystal structures, optoelectronic properties and a theoretical study.

Hughes G, Wang C, Batsanov AS, Fearn MJ, Frank S, Bryce MR, Perepichka IF, Monkman AP, Lyons BP.

Org Biomol Chem. 2003 Sep 7;1(17):3069-77. Erratum in: Org Biomol Chem. 2003 Dec 7;1(23):4359. Fearn, Michael J [correction of Fern, Michael].

PMID:
14518131

Supplemental Content

Loading ...
Support Center